SHARE - Symbicort and Health Economics in a Real Life Evaluation

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: Budesonide; Drug: Terbutaline; Drug: Formoterol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00259766

D5890L00001

SHARE

Details and patient eligibility

About

The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent,
• asthma,
• previously treated with glucocorticosteroids and B2-agonist

Exclusion criteria

• History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)